Published in Leukemia on July 01, 2004
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood (2011) 2.96
Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest (2005) 2.01
STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle (2013) 1.33
Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology (2005) 1.23
Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood (2009) 1.15
Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood (2013) 1.09
Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer (2009) 1.07
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest (2014) 0.96
Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS (2010) 0.95
Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol (2014) 0.95
Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death. Blood (2006) 0.93
Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) (2013) 0.91
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2015) 0.89
Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood (2006) 0.89
Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics (2007) 0.88
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol (2013) 0.87
Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle (2014) 0.86
Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol (2012) 0.86
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood (2016) 0.85
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget (2015) 0.84
Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget (2015) 0.84
Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood (2014) 0.82
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther (2013) 0.82
Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol (2012) 0.81
Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed (2010) 0.81
Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget (2016) 0.81
Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncotarget (2015) 0.79
Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica (2015) 0.78
STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides. Clin Cancer Res (2016) 0.78
Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70. Br J Dermatol (2010) 0.75
STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget (2016) 0.75
Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. Biomed Res Int (2016) 0.75
T-cell lymphomas, a challenging disease: types, treatments, and future. Int J Clin Oncol (2016) 0.75
Relationship between concussion and neuropsychological performance in college football players. JAMA (1999) 3.95
Lyme disease is a spirochetosis. A review of the disease and evidence for its cause. Am J Dermatopathol (1983) 3.39
A highly divergent picornavirus in a marine mammal. J Virol (2007) 2.23
Dysplastic naevus: histological criteria and their inter-observer reproducibility. Histopathology (1994) 2.09
Epidemiology of collegiate baseball injuries. Clin J Sport Med (1998) 1.85
FH3, a domain found in formins, targets the fission yeast formin Fus1 to the projection tip during conjugation. J Cell Biol (1998) 1.77
Characterization of fus1 of Schizosaccharomyces pombe: a developmentally controlled function needed for conjugation. Mol Cell Biol (1995) 1.70
Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens (2002) 1.68
The smt-0 mutation which abolishes mating-type switching in fission yeast is a deletion. Curr Genet (1993) 1.59
Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation. Differentiation (2000) 1.49
Mik1 levels accumulate in S phase and may mediate an intrinsic link between S phase and mitosis. Proc Natl Acad Sci U S A (2000) 1.46
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 1.45
Perceptions and acceptability of the female condom [Femidom] amongst commercial sex workers in the Songkla province, Thailand. Int J STD AIDS (1998) 1.45
An insight into the epidemiology of dolphin morbillivirus worldwide. Vet Microbiol (2001) 1.43
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 1.40
Two-step activation of meiosis by the mat1 locus in Schizosaccharomyces pombe. Mol Cell Biol (1995) 1.39
Assessment of pheromone production and response in fission yeast by a halo test of induced sporulation. Yeast (1994) 1.36
Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. J Immunol (1999) 1.34
Nasal T-cell lymphoma and the lethal midline granuloma syndrome. Otolaryngol Head Neck Surg (1996) 1.32
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia (2006) 1.31
Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia (2005) 1.31
Sexual differentiation in fission yeast. Trends Genet (1990) 1.30
Sequence-specific high mobility group box factors recognize 10-12-base pair minor groove motifs. J Biol Chem (2000) 1.29
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood (2001) 1.27
FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia (2007) 1.24
Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci U S A (1999) 1.22
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood (1998) 1.20
Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol (2001) 1.19
New vectors in fission yeast: application for cloning the his2 gene. Gene (1991) 1.14
Interleukin-2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes. Eur J Immunol (1994) 1.14
Light and electron microscopic studies of the paracortical post-capillary high-endothelial venules. Z Zellforsch Mikrosk Anat (1971) 1.13
Analysis of the structural genes encoding M-factor in the fission yeast Schizosaccharomyces pombe: identification of a third gene, mfm3. Mol Cell Biol (1994) 1.12
Ecosystem health as a clinical rotation for senior students in Canadian veterinary schools. Can Vet J (1997) 1.12
Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood (1998) 1.11
F-actin distribution and function during sexual differentiation in Schizosaccharomyces pombe. J Cell Sci (1998) 1.08
Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia (2008) 1.07
The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur J Immunol (1995) 1.07
Repression of a mating type cassette in the fission yeast by four DNA elements. Yeast (1991) 1.07
The bursa of Fabricius: a central organ providing for contact between the lymphoid system and intestinal content. Cell Immunol (1974) 1.07
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A (1998) 1.07
Mutations in cyr1 and pat1 reveal pheromone-induced G1 arrest in the fission yeast Schizosaccharomyces pombe. Curr Genet (1994) 1.05
Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia (2011) 1.05
Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer (2006) 1.04
The sxa2-dependent inactivation of the P-factor mating pheromone in the fission yeast Schizosaccharomyces pombe. Mol Microbiol (1996) 1.04
Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia (2013) 1.03
Localization of E-cadherin in villous, extravillous and vascular trophoblasts during intrauterine, ectopic and molar pregnancy. Mol Hum Reprod (2000) 1.02
Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain (1996) 1.01
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. J Immunol (1999) 1.01
The Schizosaccharomyces pombe mam1 gene encodes an ABC transporter mediating secretion of M-factor. Mol Gen Genet (1997) 1.01
The role of caspase 3 and BclxL in the action of interleukin 7 (IL-7): a survival factor in activated human T cells. Cytokine (1998) 1.00
Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest Ophthalmol Vis Sci (1998) 1.00
Frequency of distribution of inflammatory cytokines IL-1, IL-6 and TNF-alpha gene polymorphism in patients with obstructive sleep apnea. J Physiol Pharmacol (2008) 0.99
Airway dimensions and head posture in obstructive sleep apnoea. Eur J Orthod (1996) 0.99
Surfactant protein D in the female genital tract. Mol Hum Reprod (2004) 0.99
Modification of beta 2-microglobulin in serum from patients with small cell carcinoma of the lung--correlation with the clinical course. Clin Chim Acta (1984) 0.97
pH dependence of MHC class I-restricted peptide presentation. J Immunol (1996) 0.96
Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia (2000) 0.95
Immunomodulating activity of heparin. FASEB J (1991) 0.95
Microfibril-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung. Scand J Immunol (2006) 0.95
A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. Eur J Immunol (1994) 0.94
Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J (2001) 0.93
Leptin receptors. Eur J Med Res (2010) 0.93
The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol (1994) 0.93
Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood (2000) 0.93
Tracing the use of electrical torture. Am J Forensic Med Pathol (1984) 0.93
Antibodies to selected pathogens in free-ranging terrestrial carnivores and marine mammals in Canada. Vet Rec (2004) 0.93
Heterogeneity of antibody response to myobacterial antigens in different clinical manifestations of pulmonary tuberculosis. J Physiol Pharmacol (2007) 0.92
Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology (2000) 0.91
Modification of beta-2-microglobulin in sera from patients with small cell lung cancer: evidence for involvement of a serine protease. Clin Exp Immunol (1987) 0.91
Bcl-2, Bax, and c-Fos expression correlates to RPE cell apoptosis induced by UV-light and daunorubicin. Curr Eye Res (2000) 0.90
No association of LEPR Gln223Arg polymorphism with leptin, obesity or metabolic disturbances in children. Eur J Med Res (2009) 0.90
The scavenger receptor, cysteine-rich domain-containing molecule gp-340 is differentially regulated in epithelial cell lines by phorbol ester. Clin Exp Immunol (2002) 0.90
Functional conservation between Schizosaccharomyces pombe ste8 and Saccharomyces cerevisiae STE11 protein kinases in yeast signal transduction. Mol Gen Genet (1992) 0.90
Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol (2001) 0.90
Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. Am J Clin Pathol (2001) 0.90
Electrical and thermal injuries in pig skin--evaluated and compared by light microscopy. Forensic Sci Int (1979) 0.90
Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol (1999) 0.89
COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia (2010) 0.89
Epizootiology of morbillivirus infection in harp, hooded, and ringed seals from the Canadian Arctic and western Atlantic. J Wildl Dis (1997) 0.89
Proteolysis of the heavy chain of major histocompatibility complex class I antigens by complement component C1s. Biochim Biophys Acta (1990) 0.89
Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. J Physiol Pharmacol (2007) 0.89
Humoral immune response against mycobacterial antigens in children with tuberculosis. J Physiol Pharmacol (2006) 0.89
Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol (2003) 0.89